HPB : the official journal of the International Hepato Pancreato Biliary Association · 2026
Neoadjuvant multiagent chemotherapy or upfront surgery for primary resectable pancreatic cancer - A retrospective intention-to-treat analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Molnár Adrienne, Rodriguez Franco Salvador, Sugawara Toshitaka, Croce Chiara, Kirsch Michael J, Svensson Johan, Stoop Thomas F, Messersmith Wells A, Schulick Richard D, Franklin Oskar, Del Chiaro Marco
Аннотация
BACKGROUND: Randomized studies comparing neoadjuvant therapy and upfront surgery for primary resectable pancreatic cancer are conflicting. We aimed to determine whether multidisciplinary conference (MDC) recommendation of neoadjuvant multiagent chemotherapy is associated with survival benefits compared to upfront surgery.
METHODS: This retrospective study included patients with treatment-naive, biopsy-proven, primary resectable pancreatic adenocarcinoma discussed on MDCs at the University of Colorado Hospital in 2013-2021. Overall survival was compared by intention-to-treat, with Kaplan-Meier curves, log-rank tests, and Cox proportional hazards models.
RESULTS: Among the 221 patients included, 116 were recommended neoadjuvant multiagent chemotherapy and 105 were recommended upfront surgery. In the neoadjuvant group, 106 patients (91.4%) completed at least two months of multiagent chemotherapy. The resection rates were 87/116 (75.0%) in the neoadjuvant group and 94/105 (89.5%) in the upfront surgery group (P= 0.005). The median overall survival was 41.9 months (95% CI 23.2-62.0) in the neoadjuvant group and 23.3 months (95% CI 19.0-31.6) in the upfront surgery group. Neoadjuvant therapy recommendation was associated with improved overall survival in the adjusted Cox model (HR: 0.65; 95% CI 0.44-0.95, P= 0.027).
CONCLUSION: Neoadjuvant therapy is associated with high multiagent chemotherapy completion rates and with improved overall survival compared to upfront surgery.
METHODS: This retrospective study included patients with treatment-naive, biopsy-proven, primary resectable pancreatic adenocarcinoma discussed on MDCs at the University of Colorado Hospital in 2013-2021. Overall survival was compared by intention-to-treat, with Kaplan-Meier curves, log-rank tests, and Cox proportional hazards models.
RESULTS: Among the 221 patients included, 116 were recommended neoadjuvant multiagent chemotherapy and 105 were recommended upfront surgery. In the neoadjuvant group, 106 patients (91.4%) completed at least two months of multiagent chemotherapy. The resection rates were 87/116 (75.0%) in the neoadjuvant group and 94/105 (89.5%) in the upfront surgery group (P= 0.005). The median overall survival was 41.9 months (95% CI 23.2-62.0) in the neoadjuvant group and 23.3 months (95% CI 19.0-31.6) in the upfront surgery group. Neoadjuvant therapy recommendation was associated with improved overall survival in the adjusted Cox model (HR: 0.65; 95% CI 0.44-0.95, P= 0.027).
CONCLUSION: Neoadjuvant therapy is associated with high multiagent chemotherapy completion rates and with improved overall survival compared to upfront surgery.